Customize Consent Preferences

We use cookies to help you navigate efficiently and perform certain functions. You will find detailed information about all cookies under each consent category below.

The cookies that are categorized as "Necessary" are stored on your browser as they are essential for enabling the basic functionalities of the site. ... 

Always Active

Necessary cookies are required to enable the basic features of this site, such as providing secure log-in or adjusting your consent preferences. These cookies do not store any personally identifiable data.

Functional cookies help perform certain functionalities like sharing the content of the website on social media platforms, collecting feedback, and other third-party features.

Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics such as the number of visitors, bounce rate, traffic source, etc.

Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.

No cookies to display.

Advertisement cookies are used to provide visitors with customized advertisements based on the pages you visited previously and to analyze the effectiveness of the ad campaigns.

    Get Diamond plan for FREE

    logo

    Calithera Biosciences, Inc. (CALA)

    Price:

    0.00 USD

    ( - -0.00 USD)

    Your position:

    0 USD

    ACTION PANEL
    CREATE A NOTE
    ABOUT
    Symbol
    CALA
    Name
    Calithera Biosciences, Inc.
    Industry
    Biotechnology
    Sector
    Healthcare
    Price
    0.000
    Market Cap
    487.000
    Enterprise value
    -7.511M
    Currency
    USD
    Ceo
    Stephanie Wong
    Full Time Employees
    8
    Ipo Date
    2014-10-02
    City
    South San Francisco
    Address
    343 Oyster Point Boulevard

    Check the

    KEY TAKEAWAYS

    ASK OUR AI ABOUT THE COMPANY (REGISTER FOR EARLY ACCESS)
    Descriptive alt text

    (REGISTER FOR EARLY ACCESS) CHOOSE A PROMPT ABOVE TO ASK OUR AI ABOUT THE SPECIFIC INFORMATION

    SIMILAR COMPANIES STI SCORE

    Similar STI Score

    Nxera Pharma Co., Ltd.

    VALUE SCORE:

    6

    Symbol
    SOLTF
    Market Cap
    77.525B
    Industry
    Biotechnology
    Sector
    Healthcare

    2nd position

    Novo Nordisk A/S

    VALUE SCORE:

    11

    Symbol
    NONOF
    Market Cap
    1.414T
    Industry
    Biotechnology
    Sector
    Healthcare

    The best

    BioStem Technologies, Inc.

    VALUE SCORE:

    12

    Symbol
    BSEM
    Market Cap
    69.497M
    Industry
    Biotechnology
    Sector
    Healthcare
    FUNDAMENTALS
    P/E
    -0.000
    P/S
    0
    P/B
    0.000
    Debt/Equity
    0.082
    EV/FCF
    0.544
    Price to operating cash flow
    -1.000
    Price to free cash flow
    -1.000
    EV/sales
    0
    Earnings yield
    -37.792k
    Debt/assets
    0.058
    FUNDAMENTALS
    Net debt/ebidta
    0.622
    Interest coverage
    0
    Research And Developement To Revenue
    0
    Intangile to total assets
    0
    Capex to operating cash flow
    -0.003
    Capex to revenue
    0
    Capex to depreciation
    0.522
    Return on tangible assets
    -0.658
    Debt to market cap
    3.421k
    Piotroski Score
    0
    FUNDAMENTALS
    PEG
    -0.000
    P/CF
    -0.000
    P/FCF
    -0.000
    RoA %
    -65.790
    RoIC %
    -172.817
    Gross Profit Margin %
    0
    Quick Ratio
    3.603
    Current Ratio
    3.603
    Net Profit Margin %
    0
    Net-Net
    3.439
    FUNDAMENTALS PER SHARE
    FCF per share
    -8.762
    Revenue per share
    0
    Net income per share
    -3.779
    Operating cash flow per share
    -8.736
    Free cash flow per share
    -8.762
    Cash per share
    5.098
    Book value per share
    4.085
    Tangible book value per share
    4.085
    Shareholders equity per share
    4.085
    Interest debt per share
    0.334
    TECHNICAL
    52 weeks high
    0.005
    52 weeks low
    0.000
    Current trading session High
    0.000
    Current trading session Low
    0.000
    DIVIDEND
    Dividend yield
    0.00%
    Payout ratio
    0.00%
    Years of div. Increase
    0
    Years of div.
    0
    Q-shift
    Dividend per share
    0
    SIMILAR COMPANIES
    logo

    Country
    US
    Sector
    Healthcare
    Industry
    Biotechnology
    Dividend yield
    0%
    Payout Ratio
    0%
    P/E
    -0.000
    logo

    Country
    US
    Sector
    Healthcare
    Industry
    Biotechnology
    Dividend yield
    0%
    Payout Ratio
    0%
    P/E
    -0.000
    logo

    Country
    US
    Sector
    Healthcare
    Industry
    Biotechnology
    Dividend yield
    0%
    Payout Ratio
    0%
    P/E
    -0.000
    logo

    Country
    US
    Sector
    Healthcare
    Industry
    Biotechnology
    Dividend yield
    0%
    Payout Ratio
    0%
    P/E
    -0.001
    logo

    Country
    US
    Sector
    Healthcare
    Industry
    Biotechnology
    Dividend yield
    0%
    Payout Ratio
    0%
    P/E
    -0.000
    logo

    Country
    US
    Sector
    Healthcare
    Industry
    Biotechnology
    Dividend yield
    0%
    Payout Ratio
    0%
    P/E
    -0.001
    logo

    Country
    US
    Sector
    Healthcare
    Industry
    Biotechnology
    Dividend yield
    0%
    Payout Ratio
    0%
    P/E
    -0.000
    logo

    Country
    US
    Sector
    Healthcare
    Industry
    Medical - Specialties
    Dividend yield
    0%
    Payout Ratio
    0%
    P/E
    -0.000

    No data to display

    logo

    Country
    US
    Sector
    Healthcare
    Industry
    Biotechnology
    Dividend yield
    0%
    Payout Ratio
    0%
    P/E
    -0.000
    logo

    Country
    US
    Sector
    Healthcare
    Industry
    Biotechnology
    Dividend yield
    0%
    Payout Ratio
    0%
    P/E
    -0.000
    DESCRIPTION

    Calithera Biosciences, Inc., a clinical-stage bio-pharmaceutical company, focuses on the discovery and development of small molecule compounds for tumor metabolism and tumor immunology targets for the treatment of cancer in the United States. The company offers INCB001158, an orally bioavailable arginase inhibitor of arginase that is in Phase 1/2 clinical trial for the treatment of hematology and oncology. It is developing CB-280, an oral arginase inhibitor that has completed Phase 1b clinical trial for the treatment of cystic fibrosis and chronic airway infection; and ATG-037, an orally-bioavailable small molecule inhibitor of CD73, as well as CB-668, an orally administered inhibitor of the enzyme IL4I1. The company has a license agreement with Mars, Inc. to develop and commercialize Symbioscience's portfolio of arginase inhibitors for use in human healthcare. It also has clinical trial collaboration with Pfizer to evaluate Pfizer's PARP inhibitor talazoparib and CDK4/6 inhibitor palbociclib, each in combination with telaglenasta. In addition, the company has a collaboration and license agreement with Incyte Corporation for the research, development, and commercialization of INCB001158, a small molecule arginase inhibitor for the treatment of hematology and oncology; and a license agreement with Antengene Corporation Ltd. for the development and commercialization of CB-708. Calithera Biosciences, Inc. was incorporated in 2010 and is headquartered in South San Francisco, California.

    NEWS
    https://images.financialmodelingprep.com/news/calithera-biosciences-inc-cala-q3-2022-earnings-call-transcript-20221114.jpg
    Calithera Biosciences, Inc. (CALA) Q3 2022 Earnings Call Transcript

    seekingalpha.com

    2022-11-14 22:17:24

    Calithera Biosciences, Inc. (NASDAQ:CALA ) Q3 2022 Earnings Conference Call November 14, 2022 5:00 PM ET Company Participants Stephanie Wong - CFO & Secretary Susan Molineaux - Founder, CEO, President & Director Emil Kuriakose - Chief Medical Officer Conference Call Participants Jiale Song - Jefferies Swayampakula Ramakanth - H.C. Wainwright & Co. Matthew Cowper - SVB Securities Aydin Huseynov - Ladenburg Thalmann Operator Good day, ladies and gentlemen, and thank you for standing by.

    https://images.financialmodelingprep.com/news/calithera-biosciences-to-report-third-quarter-2022-financial-results-20221108.jpg
    Calithera Biosciences to Report Third Quarter 2022 Financial Results on Monday, November 14, 2022

    globenewswire.com

    2022-11-08 16:30:00

    SOUTH SAN FRANCISCO, Calif., Nov. 08, 2022 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage, precision-oncology biopharmaceutical company, today announced Company's third quarter 2022 financial results will be released on Monday, November 14, 2022. Company management will host a conference call on Monday, November 14, 2022, at 2:00 p.m. Pacific Time / 5:00 p.m. Eastern Time to discuss the financial results and other recent corporate highlights.

    https://images.financialmodelingprep.com/news/calitheras-stock-is-up-14-after-announcing-fast-track-20221003.jpg
    Calithera's stock is up 14% after announcing Fast Track designation for lung-cancer drug candidate

    marketwatch.com

    2022-10-03 09:08:44

    Shares of Calithera Biosciences Inc. CALA, -0.68% jumped 14.6% in premarket trading on Monday after the company said it received a Fast Track designation for its experimental treatment for non-small cell lung cancer. The drug is currently being tested in Phase 2 clinical trial.

    https://images.financialmodelingprep.com/news/3-penny-stocks-with-surprisingly-superior-fundamentals-20220909.jpg
    3 Penny Stocks With Surprisingly Superior Fundamentals

    investorplace.com

    2022-09-09 15:14:46

    The question of when to add risk to a portfolio is a difficult one to answer. A rush toward riskier equities after the pandemic-induced sell-off led to a surge in many stocks.

    https://images.financialmodelingprep.com/news/calithera-to-present-at-the-hc-wainwright-24th-annual-20220906.jpg
    Calithera to Present at the H.C. Wainwright 24th Annual Global Investment Conference

    globenewswire.com

    2022-09-06 16:05:00

    SOUTH SAN FRANCISCO, Calif., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage, precision oncology biopharmaceutical company, today announced that Susan Molineaux, Ph.D., the company's founder, president and chief executive officer, will present at the H.C. Wainwright 24th Annual Global Investment Conference, being held September 12-14 both virtually and in New York, NY.

    https://images.financialmodelingprep.com/news/calithera-biosciences-inc-cala-ceo-susan-molineaux-on-q2-20220815.jpg
    Calithera Biosciences, Inc. (CALA) CEO Susan Molineaux on Q2 2022 Results - Earnings Call Transcript

    seekingalpha.com

    2022-08-15 20:42:05

    Calithera Biosciences, Inc. (NASDAQ:CALA ) Q2 2022 Earnings Conference Call August 15, 2022 5:00 PM ET Company Participants Stephanie Wong - Chief Financial Officer Susan Molineaux - Founder, President & Chief Executive Officer Emil Kuriakose - Chief Medical Officer Conference Call Participants Jonathan Chang - SVB Securities Roger Song - Jefferies Operator Good day, and welcome to the Calithera Biosciences' Second Quarter 2022 Earnings Conference Call. At this time, all participants are in a listen-only mode.

    https://images.financialmodelingprep.com/news/what-is-a-reverse-stock-split-and-how-does-20220728.png
    What Is a Reverse Stock Split and How Does It Work?

    investorplace.com

    2022-07-28 12:42:50

    We've seen a spate of stock splits in 2022, including from high-profile companies, such as Amazon (NASDAQ: AMZN ) and Alphabet (NASDAQ: GOOG , NASDAQ: GOOGL ). But while a stock split may too familiar for you, a reverse split is not a very common corporate action.

    https://images.financialmodelingprep.com/news/what-is-a-reverse-stock-split-and-how-does-20220627.jpg
    What is a Reverse Stock Split and How Does it Work?

    investorplace.com

    2022-06-27 20:15:10

    Reverse stock splits are not that common and often are associated with some trouble brewing at the company. Therefore, one must do a thorough study before deciding what to do what with the stock of a company that just announced a reverse split.

    https://images.financialmodelingprep.com/news/calithera-to-present-at-the-hc-wainwright-global-investment-conference-20220517.jpg
    Calithera to Present at the H.C. Wainwright Global Investment Conference

    globenewswire.com

    2022-05-17 07:00:00

    SOUTH SAN FRANCISCO, Calif., May 17, 2022 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage, precision oncology biopharmaceutical company, today announced that Susan Molineaux, Ph.D., the company's founder, president and chief executive officer, will present at the H.C. Wainwright Global Investment Conference, being held May 23-25 both virtually and in Miami, FL.

    https://images.financialmodelingprep.com/news/calithera-biosciences-inc-cala-ceo-susan-molineaux-on-q1-20220510.jpg
    Calithera Biosciences, Inc. (CALA) CEO Susan Molineaux on Q1 2022 Results - Earnings Call Transcript

    seekingalpha.com

    2022-05-10 22:04:09

    Calithera Biosciences, Inc. (NASDAQ:CALA ) Q1 2022 Earnings Conference Call May 10, 2022 5:00 PM ET Company Participants Susan Molineaux - Founder, President & CEO Stephanie Wong - CFO Emil Kuriakose - Chief Medical Officer Conference Call Participants Jonathan Chang - SVB Leerink Nick Abbott - Wells Fargo Ramakanth Swayampakula - H.C. Wainwright Aydin Huseynov - Ladenburg Operator Ladies and gentlemen, thank you for standing by and welcome to Calithera Biosciences 1Q 2022 Earnings.

    https://images.financialmodelingprep.com/news/calithera-biosciences-to-report-first-quarter-2022-financial-results-on-20220503.jpg
    Calithera Biosciences to Report First Quarter 2022 Financial Results on Tuesday, May 10, 2022

    globenewswire.com

    2022-05-03 16:05:00

    SOUTH SAN FRANCISCO, Calif., May 03, 2022 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage, precision oncology biopharmaceutical company, today announced that the Company's first quarter 2022 financial results will be released on Tuesday, May 10, 2022. Company management will host a conference call on Tuesday, May 10, 2022, at 2:00 p.m. Pacific Time / 5:00 p.m. Eastern Time to discuss the financial results and other recent corporate highlights.

    https://images.financialmodelingprep.com/news/best-penny-stocks-to-buy-under-1-now-3-20220421.jpeg
    Best Penny Stocks to Buy Under $1 Now? 3 to Watch in May

    pennystocks.com

    2022-04-21 17:00:46

    Are these under $1 penny stocks on your watchlist right now? The post Best Penny Stocks to Buy Under $1 Now?

    https://images.financialmodelingprep.com/news/calithera-biosciences-inc-cala-ceo-susan-molineaux-on-q4-20220331.jpg
    Calithera Biosciences, Inc. (CALA) CEO Susan Molineaux on Q4 2021 Results - Earnings Call Transcript

    seekingalpha.com

    2022-03-31 21:49:05

    Calithera Biosciences, Inc. (CALA) CEO Susan Molineaux on Q4 2021 Results - Earnings Call Transcript

    https://images.financialmodelingprep.com/news/calithera-biosciences-raises-10m-via-equity-issued-at-10-20220330.jpg
    Calithera Biosciences Raises $10M Via Equity Issued At 10% Discount

    benzinga.com

    2022-03-30 11:27:02

    Calithera Biosciences Inc (NASDAQ: CALA) priced its previously announced underwritten public offering of 18.5 million shares at $0.54 per share for gross proceeds of $10 million. Each share of common stock is accompanied by a warrant to purchase one common share at an exercise.

    https://images.financialmodelingprep.com/news/3-hot-meme-penny-stocks-to-watch-under-3-20220328.jpg
    3 Hot Meme Penny Stocks to Watch Under $3 Right Now

    pennystocks.com

    2022-03-28 17:05:36

    Can these meme penny stocks under $3 make you money next month? The post 3 Hot Meme Penny Stocks to Watch Under $3 Right Now appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

    https://images.financialmodelingprep.com/news/calithera-biosciences-to-report-fourth-quarter-and-full-year-20220324.jpg
    Calithera Biosciences to Report Fourth Quarter and Full Year 2021 Financial Results on Thursday, March 31, 2022

    globenewswire.com

    2022-03-24 07:00:00

    SOUTH SAN FRANCISCO, Calif., March 24, 2022 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage, precision oncology biopharmaceutical company, today announced that the Company's fourth quarter and full year 2021 financial results will be released on Thursday, March 31, 2022. Company management will host a conference call on Thursday, March 31, 2021 at 2:00 p.m. Pacific Time/ 5:00 p.m. Eastern Time to discuss the financial results and other recent corporate highlights.